Rigrodsky & Long, P.A. Announces Investigation Of Obagi Medical Products, Inc. Buyout
Rigrodsky & Long, P.A.:
- Do you own shares of Obagi Medical Products, Inc. (NASDAQ GS: OMPI )?
- Did you purchase any of your shares prior to March 20, 2013?
- Do you think the proposed buyout price is too low?
- Do you want to discuss your rights?
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Obagi Medical Products, Inc. (“Obagi” or the “Company”) (NASDAQ GS: OMPI) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Valeant Pharmaceuticals International, Inc. (“Valeant”) (NYSE: VRX) in a transaction valued at approximately $344 million.
Click here to learn more: http://www.rigrodskylong.com/investigations/obagi-medical-products-inc-ompi.
Under the terms of the proposal, public shareholders of Obagi will receive $19.75 per share in cash for each share of Obagi they own.The investigation concerns whether Obagi’s board of directors failed to adequately shop the Company and obtain the best possible value for Obagi’s shareholders before entering into an agreement with Valeant. If you own the common stock of Obagi and purchased your shares before March 20, 2013, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth Rigrodsky or Brian Long at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, Delaware 19803, by telephone at (302) 295-5310, or Peter Allocco at Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, New York 11530, by telephone at (888) 969-4242; by e-mail to email@example.com, or at: http://www.rigrodskylong.com/investigations/obagi-medical-products-inc-ompi. Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States. Attorney advertising. Prior results do not guarantee a similar outcome.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts